Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
- Conditions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT03850704
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 16
- Registration Number
- NCT03661515
- Locations
- 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸Hospital la Fe, Valencia, Spain
🇪🇸Hospital Germans Tries i Pujol, Badalona, Badalona, Spain
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 17
- Registration Number
- NCT03627403
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 62
- Registration Number
- NCT03589222
- Locations
- 🇪🇸
Hospital Germans Trials i Pujol, Badalona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸Hospital ICO de Girona, Girona, Spain
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
- Conditions
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 263
- Registration Number
- NCT03555422
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇨🇦London Health Sciences Centre (London Regional Cancer Centre), London, Ontario, Canada
🇺🇸Oncology Associates of Oregon, Eugene, Oregon, United States
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
- Conditions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Morten Mau-Soerensen
- Target Recruit Count
- 25
- Registration Number
- NCT03466827
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Hospices Civils de Lyon, Lyon, France
🇫🇷Intitut Curie, Paris, France
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 11
- Registration Number
- NCT03212937
- Locations
- 🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Indolent Adult Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Extranodal Marginal Zone LymphomaRefractory Follicular LymphomaStage IV Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 69
- Registration Number
- NCT03147885
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 402
- Registration Number
- NCT03110562
- Locations
- 🇨🇦
Princess Margaret Cancer Research, Toronto, Ontario, Canada
🇺🇸Kaiser Permanente Hawaii, Honolulu, Hawaii, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT03095612
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.